Key Highlights
- Net loss was approximately USD 5.9 million, against USD 7.7 million a year earlier.
- R&D expenses were approximately USD 3.7 million, against USD 6.0 million.
- Cash and marketable securities were approximately USD 19.6 million.
- No grant Revenue was recognized, against about USD 0.3 million a year earlier.
CervoMed (NASDAQ:CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, reported financial results for the third quarter ended September 30, 2026 on November 9, 2026. Net loss was approximately USD 5.9 million, compared with approximately USD 7.7 million for the same period in 2025.
The company said the decrease was primarily due to lower total operating expenses, partially offset by a decrease in grant revenue. Its chief executive officer, Dr. John Alam, said the company believes the neflamapimod development program has been significantly de-risked through data presentations and publications this year.
Cash and Expenses
As of September 30, 2026, the company had approximately USD 19.6 million in cash, cash equivalents and marketable securities, compared with USD 20.9 million as of December 31, 2025. Based on its current operating plan, the company believes this amount funds planned operating expenses and Capital Expenditure requirements through the third quarter of 2027.
There was no grant revenue recognized in the quarter, compared with approximately USD 0.3 million in the same period of 2025. The company attributed the change to the completion of its Phase 2b RewinD-LB trial in mid-2025 and the absence of further funding under the USD 21.3 million grant from the National Institute on Aging. R&D expenses were approximately USD 3.7 million, compared with approximately USD 6.0 million, reflecting lower costs related to the completed RewinD-LB trial and lower personnel costs.
Dementia with Lewy Bodies Updates
In July 2026, the company reported clinical, plasma biomarker and MRI imaging data across five presentations at the Alzheimer's Association International Conference. In August 2026, neflamapimod received Innovation Passport designation under the United Kingdom Innovative Licensing and Access Pathway for dementia with Lewy bodies.
In September 2026, the company announced pharmacokinetic properties of a 50mg oral tablet formulation and the FDA's removal of a prior drug exposure limit for future clinical trials, supporting the use of a 100mg twice-daily dosing regimen. In October 2026, it announced publication of two peer-reviewed articles on the RewinD-LB trial.
Other Programs and Milestones
In frontotemporal dementia, the company presented initial 12-week biomarker results from its Phase 2a trial in nonfluent variant primary progressive aphasia in October 2026, showing a reduction in mean plasma neurofilament light chain levels. Management said 24-week biomarker data have been selected for presentation at CTAD 2026, held November 16 to 19, 2026 in Boston.
The company completed enrollment of 45 patients in its Phase 2a RESTORE trial in recovery after stroke. Its milestones include a Partnership to advance neflamapimod into a Phase 3 trial in dementia with Lewy bodies, and dosing of the first patient in the EXPERTS-ALS trial planned for the first quarter of 2027.
CervoMed Q3 2026 Earnings: Key Takeaways
CervoMed reported a third quarter 2026 net loss of approximately USD 5.9 million and R&D expenses of approximately USD 3.7 million. Cash, cash equivalents and marketable securities were approximately USD 19.6 million, and the company outlined neflamapimod program milestones through early 2027.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...